Short Interest in Check-Cap Ltd (NASDAQ:MBAI) Rises By 93.4%

Check-Cap Ltd (NASDAQ:MBAI) was the target of a significant growth in short interest in June. As of June 15th, there was short interest totaling 127,049 shares, a growth of 93.4% from the May 31st total of 65,685 shares. Approximately 1.8% of the shares of the company are short sold. Based on an average daily volume of 67,215 shares, the days-to-cover ratio is currently 1.9 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Check-Cap in a report on Friday, April 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Check-Cap presently has an average rating of “Sell”.

Check-Cap Trading Down 6.1%

Check-Cap stock traded down $0.08 during midday trading on Thursday, reaching $1.16. 27,522 shares of the company’s stock were exchanged, compared to its average volume of 1,298,145. The firm has a 50-day moving average price of $1.53. The company has a market cap of $8.48 million, a price-to-earnings ratio of -0.42 and a beta of 0.65. Check-Cap has a 52 week low of $0.59 and a 52 week high of $3.92.

Check-Cap Company Profile

Check-Cap Ltd. (NASDAQ: MBAI) is an Israel-based medical technology company focused on non-invasive screening solutions for colorectal cancer. The company develops an ingestible imaging capsule and associated detection system intended to provide a patient-friendly alternative to traditional colonoscopy and CT colonography for colorectal screening and polyp detection.

Check-Cap’s technology centers on a swallowable capsule that acquires images of the colon as it traverses the gastrointestinal tract; external detectors capture the transmitted signals and software reconstructs images for clinical review.